通心络胶囊联合他汀类药物治疗冠心病合并高血压疗效的Meta分析 点击下载
论文标题: 通心络胶囊联合他汀类药物治疗冠心病合并高血压疗效的Meta分析
英文标题:
中文摘要: 目的:系统评价通心络胶囊联合他汀类药物治疗冠心病合并高血压的疗效,为临床提供循证参考。方法:计算机检索PubMed、Cochrane图书馆、Embase、中国知网、维普网、万方数据和中国生物医学文献数据库,检索时限为建库起至2017年6月19日,收集在基础治疗的基础上加用通心络胶囊联合他汀类药物(试验组)对比他汀类药物(对照组)治疗冠心病合并高血压的随机对照试验(RCT),对符合纳入标准的文献进行资料提取,并采用Cochrane 5.0.1偏倚风险评估工具进行质量评价后,用Stata 14软件对总有效率、低密度脂蛋白胆固醇(LDL-C)水平、收缩压、舒张压等指标进行Meta分析。结果:共纳入9项RCT,合计714例患者。Meta分析结果显示,试验组患者在总有效率[RR=1.26,95%CI(1.16,1.36),P<0.001]、LDL-C降低水平[WMD=-0.25,95%CI(-0.39,-0.12),P<0.001]及收缩压[WMD=-5.69,95%CI(-9.33,-2.06),P=0.002]和舒张压[WMD=-2.14,95%CI    (-3.31,-0.98),P<0.001]降低程度等方面均显著优于对照组,差异均有统计学意义;两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:通心络胶囊联合他汀能显著提高冠心病合并高血压患者的总有效率,降低其LDL-C水平、收缩压及舒张压,且未增加不良事件的发生。
英文摘要: OBJECTIVE: To evaluate therapeutic efficacy of Tongxinluo capsule combined with statins in the treatment of coronary heart disease (CHD) complicated with hypertension, and to provide evidence-based reference in clinic. METHODS: Retrieved from PubMed, Cochrane library, Embase, CNKI, VIP, Wanfang database and CBM, randomized controlled trials (RCTs) about Tongxinluo capsule combined with statins on basis of basic treatment (trial group) versus statins (control group) in the treatment of CHD complicated with hypertension were collected from database establishment to June 19, 2017. After data extraction of included literatures and quality evaluation with Cochrane 5.1.0 bias risk evaluation tool, Meta-analysis of total response rate, LDL-C level, systolic blood pressure and diastolic blood pressure were conducted by using Stata 14 software. RESULTS: A total of 9 RCTs were included, involving 714 patients. Results of Meta-analysis showed that total response rate [RR=1.26,95%CI(1.16,1.36),P<0.001], the reduction of LDL-C [WMD=-0.25,95%CI(-0.39,-0.12), P<0.001], the reduction of systolic blood pressure [WMD=-5.69,95%CI(-9.33,-2.06), P=0.002] and the reduction of diastolic blood pressure [WMD=-2.14,95%CI(-3.31,-0.98), P<0.001] in trial group were significantly better than control group, with statistical significance. There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). CONCLUSIONS: Tongxinluo capsule combined with statins can significantly improve total response rate, reduce LDL-C, systolic blood pressure and diastolic blood pressure without increasing the occurrence of ADE.
期刊: 2018年第29卷第19期
作者: 耿坚雯,史桐雨,张璐,孙伟鹏,纪树亮,林潼,杨雅钦,吴伟
英文作者: GENG Jianwen,SHI Tongyu,ZHANG Lu,SUN Weipeng,JI Shuliang,LIN Tong,YANG Yaqin,WU Wei
关键字: 通心络胶囊;他汀类药物;冠心病;高血压;Meta分析
KEYWORDS: Tongxinluo capsule; Statins; Coronary heart disease; Hypertension; Meta-analysis
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!